The trypanosome alternative oxidase:a potential drug target?

New drugs against Trypanosoma brucei, the causative agent of Human African Trypanosomiasis, are urgently needed to replace the highly toxic and largely ineffective therapies currently used. The trypanosome alternative oxidase (TAO) is an essential and unique mitochondrial protein in these parasites and is absent from mammalian mitochondria, making it an attractive drug target. The structure and function of the protein are now well characterized, with several inhibitors reported in the literature which show potential as clinical drug candidates. In this review we provide an update on the functional activity and structural aspects of TAO. We then discuss TAO inhibitors reported to date, problems encountered with in vivo testing of these compounds, and discuss the future of TAO as a therapeutic target.PostprintPeer reviewe

On the extent and role of the small proteome in the parasitic eukaryote Trypanosoma brucei

Background: Although technical advances in genomics and proteomics research have yielded a better understanding of the coding capacity of a genome, one major challenge remaining is the identification of all expressed proteins, especially those less than 100 amino acids in length. Such information can be particularly relevant to human pathogens, such as Trypanosoma brucei, the causative agent of African trypanosomiasis, since it will provide further insight into the parasite biology and life cycle. Results: Starting with 993 T. brucei transcripts, previously shown by RNA-Sequencing not to coincide with annotated coding sequences (CDS), homology searches revealed that 173 predicted short open reading frames in these transcripts are conserved across kinetoplastids with 13 also conserved in representative eukaryotes. Mining mass spectrometry data sets revealed 42 transcripts encoding at least one matching peptide. RNAi-induced down-regulation of these 42 transcripts revealed seven to be essential in insect-form trypanosomes with two also required for the bloodstream life cycle stage. To validate the specificity of the RNAi results, each lethal phenotype was rescued by co-expressing an RNAi-resistant construct of each corresponding CDS. These previously non-annotated essential small proteins localized to a variety of cell compartments, including the cell surface, mitochondria, nucleus and cytoplasm, inferring the diverse biological roles they are likely to play in T. brucei. We also provide evidence that one of these small proteins is required for replicating the kinetoplast (mitochondrial) DNA. Conclusions: Our studies highlight the presence and significance of small proteins in a protist and expose potential new targets to block the survival of trypanosomes in the insect vector and/or the mammalian host

Aquaglyceroporin-null trypanosomes display glycerol transport defects and respiratory-inhibitor sensitivity

Aquaglyceroporins (AQPs) transport water and glycerol and play important roles in drug-uptake in pathogenic trypanosomatids. For example, AQP2 in the human-infectious African trypanosome, Trypanosoma brucei gambiense, is responsible for melarsoprol and pentamidine-uptake, and melarsoprol treatment-failure has been found to be due to AQP2-defects in these parasites. To further probe the roles of these transporters, we assembled a T. b. brucei strain lacking all three AQP-genes. Triple-null aqp1-2-3 T. b. brucei displayed only a very moderate growth defect in vitro, established infections in mice and recovered effectively from hypotonic-shock. The aqp1-2-3 trypanosomes did, however, display glycerol uptake and efflux defects. They failed to accumulate glycerol or to utilise glycerol as a carbon-source and displayed increased sensitivity to salicylhydroxamic acid (SHAM), octyl gallate or propyl gallate; these inhibitors of trypanosome alternative oxidase (TAO) can increase intracellular glycerol to toxic levels. Notably, disruption of AQP2 alone generated cells with glycerol transport defects. Consistent with these findings, AQP2-defective, melarsoprol-resistant clinical isolates were sensitive to the TAO inhibitors, SHAM, propyl gallate and ascofuranone, relative to melarsoprol-sensitive reference strains. We conclude that African trypanosome AQPs are dispensable for viability and osmoregulation but they make important contributions to drug-uptake, glycerol-transport and respiratory-inhibitor sensitivity. We also discuss how the AQP-dependent inverse sensitivity to melarsoprol and respiratory inhibitors described here might be exploited

Fragment screening reveals salicylic hydroxamic acid as an inhibitor of <em>Trypanosoma brucei</em> GPI GlcNAc-PI de-N-acetylase

The zinc-metalloenzyme GlcNAc-PI de-N-acetylase is essential for the biosynthesis of mature GPI anchors and has been genetically validated in the bloodstream form of Trypanosoma brucei, which causes African sleeping sickness. We screened a focused library of zinc-binding fragments and identified salicylic hydroxamic acid as a GlcNAc-PI de-N-acetylase inhibitor with high ligand efficiency. This is the first small molecule inhibitor reported for the trypanosome GPI pathway. Investigating the structure activity relationship revealed that hydroxamic acid and 2-OH are essential for potency, and that substitution is tolerated at the 4- and 5-positions

Investigating the Role of RNA-Binding Protein 5 in the Life Cycle Differentiation of Trypanosoma Brucei

Trypanosomatid parasites such as Trypanosoma brucei have unusual mechanisms of gene expression including polycistronic transcription, mitochondrial RNA editing and trans-splicing. Additionally, these protists rely mainly on post-transcriptional regulation where RNA-binding proteins (RBP) have shown to play a major role. RBP6 and RBP10 are two examples of RBPs that play crucial roles in procyclic and bloodstream form parasites differentiation respectively, by post-transcriptional regulation. Over-expression of RBP6 is enough to promote differentiation into metacyclic trypomastigotes that are infective to mice. However, continuous expression is required, and this pattern does not reflect the natural expression in the tsetse fly or the influence of other RNA-binding proteins. RBP5 is a RBP with a single RNA-recognition motif similar to RBP6 and RBP10, whose expression is upregulated during the life stages within the salivary glands of tsetse flies. We hypothesize the RBP5 facilitates metacyclogenesis in the tsetse fly. To evaluate possible contributions to T. brucei differentiation, we will over-express RBP5 in procyclic cells alone and in combination with RBP6. Initial screening of cells over-expressing PTP-tagged RBP5 resulted in parasites with a moderate growing defect, and the scoring of nuclei and kinetoplasts in fixed cells showed a progressive accumulation of cells with 2 nuclei and 2 kinetoplasts (2N2K) and appearance of multinucleated cells. On the other hand, over-expression of non-tagged RBP5 generated a more severe growing defect, starting immediately after the first day of induction. The scoring of nuclei and kinetoplasts resulted in a drastic increase of 2N2K cells and a greater appearance of multinucleated cells, which suggests an irregular cell cycle progression. When developing the dual over-expression system, our cells over-expressing RBP6 were not able to differentiate into any stage, and when over-expressing RBP5 and RBP6 coordinately, no differentiation process was observed either. Together these data suggest that RBP5 might be a regulator of genes involved in the initiation of cytokinesis in T. brucei parasites, however a role in metacyclogenesis cannot be discarded since we were not able to obtain metacyclic parasites. This study helped us to get a better understanding of the post-transcriptional regulatory mechanisms that repress and regulate T. brucei cell cycle progression

Coenzyme Q2 is a universal substrate for the measurement of respiratory chain enzyme activities in trypanosomatids

The measurement of respiratory chain enzyme activities is an integral part of basic research as well as for specialized examinations in clinical biochemistry. Most of the enzymes use ubiquinone as one of their substrates. For current in vitro measurements, several hydrophilic analogues of native ubiquinone are used depending on the enzyme and the workplace. We tested five readily available commercial analogues and we showed that Coenzyme Q2 is the most suitable for the measurement of all tested enzyme activities. Use of a single substrate in all laboratories for several respiratory chain enzymes will improve our ability to compare data, in addition to simplifying the stock of chemicals required for this type of research

The bloodstream differentiation - division of Trypanosoma brucei studied using mitochondrial markers

In the bloodstream of its mammalian host, the African trypanosome Trypanosoma brucei undergoes a life cycle stage differentiation from a long, slender form to a short, stumpy form. This involves three known major events: exit from a proliferative cell cycle, morphological change and mitochondrial biogenesis. Previously, models have been proposed accounting for these events (Matthews & Gull 1994a). Refinement of, and discrimination between, these models has been hindered by a lack of stage-regulated antigens useful as markers at the single-cell level. We have now evaluated a variety of cytological markers and applied them to investigate the coordination of phenotypic differentiation and cell cycle arrest. Our studies have focused on the differential expression of the mitochondrial enzyme dihydrolipoamide dehydrogenase relative to the differentiation-division of bloodstream trypanosomes. The results implicate a temporal order of events: commitment, division, phenotypic differentiation

Mitochondrion targeted trypanosome alternative oxidase inhibitors as chemotherapeutic agents against T. brucei

Trabajo presentado en el XII SEQT Mini Symposium. IIIrd Spanish/Portuguese/Brazilian Meeting, celebrado en Madrid del 17 al 18 de noviembre de 2016.During their life-cycle, trypanosomes adapt their energy metabolism to the availability of nutrients in their environment. Hence, procyclic forms of T. brucei have a fully functional respiratory chain and synthesize ATP by oxidative phosphorylation in the mitochondrion. In contrast, respiration of bloodstream forms (BSF) of T. brucei (i.e. the human-infective form) relies exclusively on glycolysis for energy production. The trypanosome alternative oxidase (TAO) is the sole terminal oxidase enzyme to re-oxidize NADH accumulated during glycolysis. It is a cyanide-resistant and cytochrome-independent ubiquinol oxidase which is sensitive to the specific inhibitors salicylhydroxamic acid (SHAM) and ascofuranone. This enzyme which is essential to the viability of BSF trypanosomes and has no counterpart in the mammalian host is a potential target for chemotherapy. To boost the activity of TAO inhibitors against T. brucei, we investigated a chemical strategy consisting in the conjugation of the inhibitor with lipophilic cations (LC) that can cross lipid bilayers by non-carrier mediated transport, and thus accumulate specifically into the mitochondrion, driven by the plasma and mitochondrial transmembrane potentials (negative inside). This design afforded several LC¿TAO inhibitor conjugates active in the submicromolar to low nanomolar range against wild type and resistant strains of African trypanosomes (T. b. brucei, T. congolense). Selectivity over human cells was >500. Studies of the effects on purified TAO, parasite respiration, mitochondrial membrane potential (¿m), and cell cycle suggest that TAO is a likely target of the compounds in vivo

Kontrola tripanosomoze kemoterapeuticima - pregled prošlih mjera, sadašnje stanje i budući trendovi

African trypanosomosis is a major parasitic disease which affects both humans and animals in the Africa continent, south of the Sahara desert. It is caused by infection with various species of trypanosome that are transmitted to the host through the bite of an infected vector, the tsetse fly. Efforts to control the disease have involved attempts to reduce the vector population by use of traps, insecticide application, the sterile male technique as well as treatment and prophylaxis of overt cases with chemotherapeutic drugs, consisting mainly of isometamidium, homidium, quinapyramine and diminazene. These drugs have been in use for over 50 years and are associated with severe toxicity and parasite resistance. Over the years, efforts in several laboratories to formulate new treatment profiles through pharmacokinetic studies of the trypanocides, combination therapy, use of medicinal plants and application of antioxidants, have not succeeded in eradicating the threat of the disease. The development of an effective vaccine has also not been successful due to the antigenic variation of the trypanosome surface coat, a condition that has stifled progress, if not totally halted vaccine development. However, more recent studies suggest the trypanosomal microtubulin could be a viable antigen for vaccine development. This review focuses on measures that have been undertaken to control Animal African Trypanosomosis by chemotherapy, and discusses future measures and prospects since the measures adopted so far have not successfully controlled the disease.Afrička tripanosomoza glavna je nametnička bolest ljudi i životinja na afričkom kontinentu južno od Sahare. Njezini su uzročnici različite vrste tripanosoma koje se prenose na domaćina ubodom zaraženog prijenosnika muhe ce-ce. Napori koji se ulažu u kontroli bolesti uključuju i pokušaje za smanjenje populacije prijenosnika uporabom klopki, primjenom insekticida, postupkom sterilnih mužjaka kao i liječenjem te profilaksom kemoterapeuticima poput izometamidija, homidija, kvinapiramina i diminazena. Ti su lijekovi u uporabi više od pedeset godina i povezani su s teškom toksičnošću organizma i otpornošću parazita. Prijetnja od ove bolesti nije uklonjena unatoč višegodišnjim naporima nekih laboratorija za pronalaženje novih oblika liječenja proučavanjem farmakokinetike tripanocida, zatim kombiniranom terapijom, uporabom medicinskog bilja te primjenom antioksidansa. Ni razvoj učinkovitog cjepiva nije bio uspješan, zbog antigenskih promjena na površinskoj ovojnici tripanosoma. To je smanjilo nade za napredak u razvoju cjepiva, ako ga nije i potpuno zaustavilo. Ipak, najnovija istraživanja pokazuju da bi tripanosomski mikrotubulin mogao biti održiv antigen za razvoj cjepiva. Ovaj je pregledni članak usredotočen na mjere poduzimane za kontrolu tripanosomoze u afričkih životinja kemoterapijom. U njemu se također razmatraju buduće mjere i perspektive s obzirom na to da dosadašnje mjere nisu bile uspješne u kontroli bolesti